Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies

por Pommeret, F., Colomba, J., Bigenwald, C., Laparra, A., Bockel, S., Bayle, A., Michot, J.-M., Hueso, T., Albiges, L., Tiberghien, P., Marot, S., Jary, A., Lacombe, K., Barlesi, F., Griscelli, F., Colomba, E.
Publicado 2021